Lunai Bioworks (LNAI) Cost of Revenue (2013 - 2016)

Lunai Bioworks (LNAI) posted quarterly Cost of Revenue of $31.0 for Q2 2016, down 99.99% quarter-over-quarter from $258278.0 in Q1 2015.

Lunai Bioworks (LNAI) Cost of Revenue (2013 - 2016) Analysis & Trends

Lunai Bioworks' Cost of Revenue history runs 4 years deep, the most recent figure standing at $31.0 for Q2 2016.

In Q2 2016, Cost of Revenue changed N/A year-over-year to $31.0; the TTM figure through Mar 2026 stood at $471965.0 (changed N/A YoY), while the FY2016 annual figure was $5275.0, down 92.0% from the prior year.
Cost of Revenue for Q2 2016 stood at $31.0, down from $258278.0 in the prior quarter.
The five-year high for Cost of Revenue was $258278.0 in Q1 2015, with the low at $31.0 in Q2 2016.
The 4-year median for Cost of Revenue is $64266.0 (2014), against an average of $92622.1.
The sharpest annual moves came in 2014 and 2015: Cost of Revenue increased 15.49% in 2014, then jumped 1355.99% in 2015.
Lunai Bioworks' Cost of Revenue stood at $68486.0 in 2013, then surged by 211.97% to $213656.0 in 2014, then climbed by 20.88% to $258278.0 in 2015, then slumped by 99.99% to $31.0 in 2016.
Business Quant data shows LNAI's Cost of Revenue at $31.0 in Q2 2016, $258278.0 in Q1 2015, and $213656.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	145.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	93.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	174.53 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	298.26 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	387.98 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	67.21 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00	-

Download Data